DV treatment was delayed until PSD 7 in order to determine whether it could have a broad therapeutic window for experimental stroke as well as to distinguish potential DV effects on neurorepair mechanisms from more acute (e.g., PSD1 to PSD 3) neuroprotective effects [7]. This evidence concerns the gene PSD and Stroke.